Video Review: Talking Biopolitics
By Rebecca Dimond,
BioNews
| 10. 12. 2015
[cites CGS and CGS fellow Lisa Ikemoto]
Untitled Document
Watch Talking Biopolitics with George Annas and Lisa Ikemoto on YouTube
Genomic medicine has advanced rapidly in recent years and, with our increasing capacity to collect and store genetic information, it holds not only great promise but also pitfalls, for individuals and communities. This was the topic under discussion in a live video conversation on 7 October, organised by the Center for Genetics and Society.
The conversation was between Professor Lisa Ikemoto of the University of California, who was interviewing Professor George Annas, Director of the Center of Health Law, Ethics and Human Rights at Boston University, about his book Genomic Messages: How the Evolving Science of Genetics Affects our Health, Families, and Future'.
Professor Annas and his co-writer Sherman Elias (an obstetrician-gynaecologist, who died last year) have written a book that addresses important issues. The blurb on the back refers to 'an uncertain time' and one that is 'fraught with understandable and uncomfortable questions'. So I was intrigued to discover what topics the conversation would cover, and what 'uncomfortable questions' it might address.
Professor Annas...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...